Browse the evidence

Tirzepatide produces the greatest weight loss and superior cardiometabolic improvements (blood pressure, triglycerides, glucose) among FDA/EMA-approved anti-obesity medications.

If you have obesity and comorbidities, Tirzepatide is currently the most effective FDA-approved medication for weight loss and improving metabolic markers like blood pressure and blood sugar. It outperforms Semaglutide in weight reduction magnitude.

Moderate weight loss (7-10% of initial body weight) significantly reduces ectopic lipid content in the liver, pancreas, and visceral adipose tissue, with liver lipid reduction being the strongest independent predictor of improved insulin resistance.

Losing just 7-10% of your body weight through a moderate caloric deficit (500 kcal/day below maintenance) can drastically reduce fat stored in your liver and pancreas. This specific reduction in ectopic fat is more critical for fixing insulin resistance than just losing belly fat. Focus on sustainable, moderate weight loss rather than extreme diets to see significant metabolic health improvements.

Sprint Interval Training (SIT) reduces abdominal visceral fat area (AVFA) to a similar extent as High-Intensity Interval Training (HIIT) despite requiring significantly less total exercise time and training load.

If you are obese and want to reduce dangerous belly fat, Sprint Interval Training (SIT) is a viable option that saves time compared to traditional HIIT. Perform 80 cycles of 6-second all-out sprints with 9 seconds of rest, 3-4 times a week. You do not need to match the total work or time of longer HIIT sessions to see significant visceral fat loss.

Maintaining weight loss after formula diet-induced weight loss requires specific strategies, including continued use of formula products, behavioral support, and gradual food reintroduction, as physiological hunger hormones (ghrelin) increase post-weight loss.

After losing weight with formula meals, your body will naturally try to regain it by increasing hunger hormones. To keep the weight off, you must actively maintain your progress. This means continuing to use some formula products (daily or periodically), engaging in behavioral strategies like self-monitoring, and slowly reintroducing solid foods over 6 weeks rather than rushing back to normal eating.

Tirzepatide significantly reduces body weight, BMI, and waist circumference in overweight or obese adults without diabetes compared to placebo.

If you are overweight or obese and do not have diabetes, tirzepatide is a highly effective prescription medication for significant weight loss. It is taken once a week by injection. While it causes side effects like nausea and vomiting in many people, the weight loss benefits are substantial. You should discuss the risks and benefits with your doctor and start with a low dose to minimize side effects.

Lorcaserin (10 mg twice daily) produces significant weight loss and improves cardiometabolic risk factors in obese adults by selectively activating 5-HT2C receptors to reduce energy intake without increasing energy expenditure.

Take 10mg of Lorcaserin twice daily, ideally before breakfast and dinner, while following a lifestyle program that creates a moderate caloric deficit. This medication works by reducing your appetite through specific brain receptors, leading to significant weight loss and improved metabolic markers like blood pressure and cholesterol without increasing your energy expenditure.

Whey protein supplementation combined with resistance training significantly improves body composition (lean mass gain and fat mass loss) and muscular strength specifically in individuals under 40 years of age, but not in older individuals.

If you are under 40, whey protein after resistance training is a proven strategy to build muscle and lose fat. If you are over 40, this specific combination may not yield the same results, and you should consider discussing multi-nutrient options (like vitamin D and leucine-enriched whey) with a professional.

Combining sibutramine (10-15 mg/day) with a low-calorie diet using meal replacements and behavioral modification significantly improves both weight loss and long-term weight maintenance compared to diet and behavioral modification alone.

To lose weight and keep it off, combine a prescription medication (sibutramine) with a structured low-calorie diet that includes meal replacement shakes and behavioral counseling. This combination was significantly more effective than diet and counseling alone in maintaining weight loss over 12 months.

Sibutramine (15 mg daily) combined with lifestyle interventions produces significant weight reduction and improves metabolic risk factors in obese women with polycystic ovary syndrome (PCOS).

If you have PCOS and are overweight, sibutramine (15mg daily) combined with standard diet and exercise advice can help you lose significantly more weight than lifestyle changes alone. It also improves metabolic markers like triglycerides. Discuss this option with your doctor, especially since other common PCOS drugs like Metformin are not primarily effective for weight loss.

Time-restricted eating (TRE) significantly reduces body weight and fasting insulin levels in overweight and obese women compared to control groups, without negatively affecting fat-free or lean body mass.

If you are overweight or obese, try restricting your eating window to 8-10 hours a day (e.g., 10 AM to 6 PM). This approach has been shown to help women lose weight and improve insulin sensitivity without losing muscle mass, and it is often easier to stick to than strict calorie counting.

Lactobacillus sp. probiotic supplementation significantly reduces body mass index, body weight, waist and hip circumference, and visceral/subcutaneous fat mass in non-comorbid obese individuals compared to placebo.

If you are obese without other major health conditions, adding a Lactobacillus probiotic (doses ranging from 1 million to 50 billion CFU daily) to your routine may help reduce body weight, BMI, and waist circumference. The effect is modest but statistically significant, particularly when taken for at least 12 weeks. It is not a magic bullet but may support other lifestyle changes.

In adults with obesity without diabetes, tirzepatide produces significantly greater weight loss and cardiometabolic improvements than semaglutide over 6 months, even when semaglutide patients receive higher maintenance doses.

If you are choosing between tirzepatide and semaglutide for obesity management without diabetes, tirzepatide offers greater weight loss and better cardiometabolic improvements over 6 months. This advantage holds true even if you are on a higher maintenance dose of semaglutide than the typical tirzepatide dose. Consult your doctor to determine which medication aligns best with your health profile and insurance coverage.

Tirzepatide (TZP) significantly reduces total fat mass, visceral adipose tissue, and waist circumference in individuals with overweight or obesity, with effects superior to other anti-obesity medications like dulaglutide and semaglutide.

Tirzepatide is a highly effective weekly injectable treatment for obesity that significantly reduces fat mass and visceral fat, outperforming other common medications like semaglutide. While it does cause some loss of lean mass, the disproportionate loss of fat leads to improved body composition ratios. Patients should expect weekly injections and potential gastrointestinal side effects, but the long-term benefits for body fat distribution are substantial.

Six months of intermittent fasting (2-3 non-consecutive days of vegetable-only fasting per week) significantly reduces body weight, body fat, and improves lipid profiles (LDL-C, non-HDL-C, triglycerides) in middle-aged adults with overweight, without significantly affecting blood pressure, fasting glucose, or inflammatory markers.

If you are overweight and middle-aged, trying intermittent fasting 2-3 days a week with a vegetable-only diet on those days can significantly improve your weight and cholesterol levels without needing to change your diet on other days. This approach is well-tolerated and offers specific metabolic benefits beyond just eating less.

Flexible time-restricted eating combined with aerobic exercise improves insulin resistance (HOMA-IR) and insulin levels more effectively than either intervention alone.

To improve your insulin sensitivity, combining an 8-hour eating window with regular moderate aerobic exercise is more effective than doing either one alone. This approach helps lower insulin levels and improve insulin resistance markers more significantly than diet or exercise in isolation.

Semaglutide 2.4 mg weekly produces substantial and durable weight loss (10-15%) in adults with overweight or obesity through central appetite suppression, delayed gastric emptying, and improved glucose homeostasis.

If you have obesity, semaglutide 2.4 mg taken once weekly is a highly effective treatment for significant weight loss (10-15%). It works by reducing appetite and slowing digestion. Start with a low dose to minimize stomach upset, which usually improves over time. It is a long-term commitment, not a quick fix.

Short sleep duration (≤5-6 hours per night) is associated with a significantly increased risk of coronary heart disease (RR 1.48) and stroke (RR 1.15) compared to the reference group of 7-8 hours.

Aim for 7-8 hours of sleep per night. Consistently sleeping 5 hours or less per night is associated with a significantly higher risk of heart disease and stroke. While you cannot change your genetics, prioritizing sleep duration is a modifiable risk factor for cardiovascular health.

Letrozole is the first-line pharmacological therapy for infertility in women with PCOS, superior to or preferred over Clomiphene and Metformin.

If you are trying to conceive, Letrozole is the recommended first medication. Clomiphene and Metformin are used if Letrozole is not suitable or effective.

GLP-1 receptor agonists (e.g., Liraglutide, Exenatide) promote weight loss and improve glycemic control by mimicking incretin hormones, delaying gastric emptying, and increasing satiety, making them advantageous for obese T2DM patients.

GLP-1 agonists like Liraglutide are injectable medications that help lower blood sugar and promote weight loss. They work by mimicking a natural hormone that slows digestion and increases fullness. They are particularly useful for obese patients. Hypoglycemia risk is low unless taken with other specific diabetes drugs.

Exenatide (5-10 mcg twice daily) significantly improves glycemic control (HbA1c reduction of 0.46-0.86%) and promotes progressive weight loss in type 2 diabetes patients failing sulfonylurea monotherapy, without causing severe hypoglycemia.

If you have type 2 diabetes and your current sulfonylurea medication isn't controlling your blood sugar well, adding exenatide (a once- or twice-daily injection) can significantly lower your HbA1c and help you lose weight. While you might experience some nausea or mild hypoglycemia initially, these side effects often decrease over time, and the medication does not cause severe hypoglycemia on its own. It is a viable option for improving glycemic control when other treatments fail.

Increasing dietary fiber intake, particularly insoluble fiber from whole grains, is inversely related to the risk of developing type two diabetes and improves insulin sensitivity.

To lower your risk of type two diabetes, prioritize insoluble fiber from whole grains (like bran) over just soluble fiber. Studies show that consuming around 26g of fiber daily (compared to 13g) can lower your risk by 22%. Focus on whole cereal grains rather than just fruits or vegetables for this specific benefit.

Increasing dietary fiber intake is associated with decreased body weight or attenuated weight gain, primarily through mechanisms involving increased satiety hormones (GLP-1, PYY) and decreased metabolizable energy.

To manage weight, increase your fiber intake by about 8g per 1000 kcal. This can lead to modest weight loss (approx. 4.4 lbs over 20 months in one study). If you eat a high-fat diet, prioritize insoluble fiber (like bran) as soluble fiber might not help and could potentially increase energy absorption in that context.

A population-wide reduction of dietary salt by 3 g per day (approx. 1200 mg sodium) significantly reduces the incidence of coronary heart disease, stroke, and myocardial infarction, and lowers all-cause mortality.

Reduce your daily salt intake by approximately 3 grams (about 1200 mg of sodium). This is a significant public health target, not just a minor tweak. Focus on processed foods, which provide 75-80% of dietary salt. The benefits include fewer heart attacks, strokes, and deaths, and it is cost-saving for the healthcare system. Start gradually if needed, as your taste buds will adapt.

Interrupting prolonged sitting with brief (2-minute) bouts of light- or moderate-intensity walking every 20 minutes significantly reduces postprandial glucose and insulin responses in overweight/obese adults compared to uninterrupted sitting.

If you have a desk job or sit for long periods, do not sit continuously. Stand up and walk lightly or at a moderate pace for just 2 minutes every 20 minutes. This simple break significantly lowers your blood sugar and insulin spikes after meals, offering cardiovascular benefits comparable to a full workout without requiring extra time or high intensity.